Presentation is loading. Please wait.

Presentation is loading. Please wait.

G. Catho, S. Couraud, S. Grard, A. Bouaziz, A. Sénéchal, F. Valour, T

Similar presentations


Presentation on theme: "G. Catho, S. Couraud, S. Grard, A. Bouaziz, A. Sénéchal, F. Valour, T"— Presentation transcript:

1 Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting 
G. Catho, S. Couraud, S. Grard, A. Bouaziz, A. Sénéchal, F. Valour, T. Perpoint, E. Braun, F. Biron, T. Ferry, C. Chidiac, N. Freymond, E. Perrot, P.-J. Souquet, J.-M. Maury, F. Tronc, N. Veziris, G. Lina, O. Dumitrescu, F. Ader  Clinical Microbiology and Infection  Volume 21, Issue 5, Pages 472.e7-472.e10 (May 2015) DOI: /j.cmi Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2 Fig. 1 Summary of multidrug-resistant (MDR) tuberculosis (TB) patients who achieved intensive and continuation phases with the recommended number of drugs, and the current status of ongoing treatments (the intensive phase lasted for 8 months, and the continuation phase lasted for 12 months). AMK, amikacin. Clinical Microbiology and Infection  , 472.e7-472.e10DOI: ( /j.cmi ) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions


Download ppt "G. Catho, S. Couraud, S. Grard, A. Bouaziz, A. Sénéchal, F. Valour, T"

Similar presentations


Ads by Google